Title
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study
Date Issued
15 June 2015
Access level
open access
Resource Type
journal article
Author(s)
Luetkemeyer A.F.
Rosenkranz S.L.
Lu D.
Grinsztejn B.
Sanchez J.
Ssemmanda M.
Sanne I.
Mcilleron H.
Havlir D.V.
Haas D.W.
Publisher(s)
Oxford University Press
Abstract
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
Start page
1860
End page
1863
Volume
60
Issue
12
Language
English
OCDE Knowledge area
Biología celular, Microbiología
Enfermedades infecciosas
Subjects
Scopus EID
2-s2.0-84983320521
PubMed ID
Source
Clinical Infectious Diseases
ISSN of the container
10584838
Sponsor(s)
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award Numbers UM1 AI068634, UM1 AI068636 and UM1 AI106701. Additional grant support included AI077505, TR000445 (D. W. H.) and National Research Foundation of South Africa 90729 (H. M.). Antiretroviral medications were donated by Gilead Sciences and Merck Pharmaceuticals.
Financial support. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award Numbers UM1 AI068634, UM1 AI068636 and UM1 AI106701. Additional grant support included AI077505, TR000445 (D. W. H.) and National Research Foundation of South Africa 90729 (H. M.). Antiretroviral medications were donated by Gilead Sciences and Merck Pharmaceuticals.
Sources of information:
Directorio de Producción Científica
Scopus